By Colin Kellaher
Spero Therapeutics has named Esther Rajavelu chief financial and business officer of the clinical-stage biopharmaceutical company.
The Cambridge, Mass., company on Wednesday said Rajavelu most recently served as chief financial officer of Fulcrum Therapeutics, which announced her departure earlier this year.
Spero said Rajavelu, 45 years old, will receive an annual base salary of $475,000 and an annual bonus with a target of 40% of her base pay.
Stephen DiPalma, a managing director at financial consultancy Danforth Advisors, has been serving as Spero’s interim chief financial officer since the elevation of Satyavrat Shukla to president and chief executive on Aug. 1.
Write to Colin Kellaher at colin.kellaher@wsj.com
Read the full article here
